To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in patients with pulmonary arterial hypertension PAH, who live permanently \>2600m.
Adult patients aged 18-80 years and of all genders
Permanent residence > 2600 m
Diagnosis of pulmonary arterial hypertension PAH (PAHHA-Group) according to guidelines
Patients are stable on therapy
Age <18 years or >80 years
unstable condition
Patients who cannot follow the study investigations
Patient permanently living < 2600m.
Single group
Descent from 2850m to sea level
BehavioralDescent from 2850m to sea level with a stay for 7 days
Pulmonary resistance (sPAP/CO) after 7 days at sea level
Difference in sPAP/CO by echocardiography between 2850m and Day 5-7 at sea level in patients with pulmonary arterial hypertension
Tricuspid regurgitation velocity TRV after 7 days at sea level
Difference in tricuspid regurgitation velocity TRV between 2850m and Day 5-7 at sea level in patients with pulmonary arterial hypertension
Cardiac output CO after 7 days at sea level
Difference/change in cardiac output CO between 2850m and Day 5-7 at sea level in patients with pulmonary arterial hypertension
Tricuspid annular plan systolic excursion TAPSE after 7 days at sea level
Difference/change in tricuspid annular plan systolic excursion TAPSE between 2850m and Day 5-7 at sea level in patients with pulmonary arterial hypertension
Right ventricular strain after 7 days at sea level
Difference/change in right ventricular strain between 2850m and day 5-7 at sea level in patients with pulmonary arterial hypertension
Click on the lead sponsor to view all of their trials.
Silvia Ulrich Somaini
Lead sponsor
University of Zurich
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options:
